Abstract
Brain angiotensin-(1-7) (Ang-(1-7)) concentration has been shown to be reduced and inversely correlated with tau pathology in a mouse model of Alzheimer’s disease (AD). In this study, to determine whether the concentration of Ang-(1-7) and the activity of its converting enzyme angiotensin-converting enzyme 2 were altered in plasma under AD context, the plasma samples from 110 AD patients and 128 age- and gender-matched controls were screened. In AD patients, the plasma concentration of Ang-(1-7) was significantly reduced (15.63±4.35pg/mL vs. 19.58±3.22pg/mL, P<0.001) and positively correlated with cognitive functions (R=0.66, P<0.001). Meanwhile, receiver-operating characteristic analysis showed that the Ang-(1-7) concentration in plasma could distinguish AD patients from controls with the sensitivity and specificity of 69.1% and 74.2%, respectively, when the optimal cut-off value (18.2 pg/mL) was chosen. These findings indicate that plasma Ang-(1-7) may represent a potential biomarker for AD diagnosis, and further suggest an involvement of this heptapeptide in the pathogenesis of this disease.
Keywords: Alzheimer’s disease, Renin-angiotensin system, angiotensin-(1-7), ACE2, plasma, biomarker.
Current Neurovascular Research
Title:Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer’s Disease
Volume: 13 Issue: 2
Author(s): Teng Jiang, Lan Tan, Qing Gao, Huan Lu, Xi-Chen Zhu, Jun-Shan Zhou and Ying-Dong Zhang
Affiliation:
Keywords: Alzheimer’s disease, Renin-angiotensin system, angiotensin-(1-7), ACE2, plasma, biomarker.
Abstract: Brain angiotensin-(1-7) (Ang-(1-7)) concentration has been shown to be reduced and inversely correlated with tau pathology in a mouse model of Alzheimer’s disease (AD). In this study, to determine whether the concentration of Ang-(1-7) and the activity of its converting enzyme angiotensin-converting enzyme 2 were altered in plasma under AD context, the plasma samples from 110 AD patients and 128 age- and gender-matched controls were screened. In AD patients, the plasma concentration of Ang-(1-7) was significantly reduced (15.63±4.35pg/mL vs. 19.58±3.22pg/mL, P<0.001) and positively correlated with cognitive functions (R=0.66, P<0.001). Meanwhile, receiver-operating characteristic analysis showed that the Ang-(1-7) concentration in plasma could distinguish AD patients from controls with the sensitivity and specificity of 69.1% and 74.2%, respectively, when the optimal cut-off value (18.2 pg/mL) was chosen. These findings indicate that plasma Ang-(1-7) may represent a potential biomarker for AD diagnosis, and further suggest an involvement of this heptapeptide in the pathogenesis of this disease.
Export Options
About this article
Cite this article as:
Jiang Teng, Tan Lan, Gao Qing, Lu Huan, Zhu Xi-Chen, Zhou Jun-Shan and Zhang Ying-Dong, Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer’s Disease, Current Neurovascular Research 2016; 13 (2) . https://dx.doi.org/10.2174/1567202613666160224124739
DOI https://dx.doi.org/10.2174/1567202613666160224124739 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patenting Penicillium Strains
Recent Patents on Biotechnology Vitamin D Biology in Heart Failure: Molecular Mechanisms and Systematic Review
Current Drug Targets Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease
Current Medicinal Chemistry Gestational Programming of Offspring Obesity: A Potential Contributor to Alzheimers Disease
Current Alzheimer Research How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?
Current Cardiology Reviews Human Induced Pluripotent Stem Cells for Inherited Cardiovascular Diseases Modeling
Current Stem Cell Research & Therapy Alzheimers and Dementia in the Oldest-Old: A Century of Challenges
Current Alzheimer Research Bisthiourea Derivatives of Dipeptide Conjugated Benzo[d]isoxazole as a New Class of Therapeutics: Synthesis and Molecular Docking Studies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Progress Towards the Development of DHQO Derivatives and Related Analogues with Inotropic Effects
Mini-Reviews in Medicinal Chemistry Antitumor Activity of Magnetite Nanoparticles: Influence of Hydrocarbonated Chain of Saturated Aliphatic Monocarboxylic Acids
Current Organic Chemistry Cell-free Nucleic Acids as a Non-Invasive Route for Investigating Atherosclerosis
Current Pharmaceutical Design Cellular Localisation of Chromogranins and Processed Products in the Diffuse Neuroendocrine System and Related Tumours
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Inhibition of Platelet Adhesion to Collagen as a New Target for Antithrombotic Drugs
Current Drug Targets - Cardiovascular & Hematological Disorders Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Current Pharmaceutical Design Cardiovascular Risk Factors: Does Sex Matter?
Current Vascular Pharmacology Cell Therapy for the Treatment of Chronic Ischemic Heart Disease
Current Pharmaceutical Design The Complementary Roles of Imaging and ‘Omics’ for Future Anti-Atherosclerotic Drug Development
Current Pharmaceutical Design Editorial (Hot Topic:Current Situation at Perioperative of Cardiovascular Disease Patients: New Addressing and Perioperative Optimization Techniques)
Current Pharmaceutical Design The Role of Neopterin in Atherogenesis and Cardiovascular Risk Assessment
Current Medicinal Chemistry